# Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

> **NCT01118091** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Skin Cancer
- Melanoma
- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** CD8 enriched Young TIL

## Key facts

- **NCT ID:** NCT01118091
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118091, "Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01118091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*